1. Home
  2. SDGR vs CRVS Comparison

SDGR vs CRVS Comparison

Compare SDGR & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SDGR

Schrodinger Inc.

HOLD

Current Price

$18.76

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Logo Corvus Pharmaceuticals Inc.

CRVS

Corvus Pharmaceuticals Inc.

HOLD

Current Price

$14.48

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SDGR
CRVS
Founded
1990
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.1B
IPO Year
2020
2016

Fundamental Metrics

Financial Performance
Metric
SDGR
CRVS
Price
$18.76
$14.48
Analyst Decision
Buy
Strong Buy
Analyst Count
9
6
Target Price
$21.00
$30.17
AVG Volume (30 Days)
999.0K
856.0K
Earning Date
05-05-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
45.14
48.04
EPS
N/A
N/A
Revenue
$255,869,000.00
N/A
Revenue This Year
$0.76
N/A
Revenue Next Year
$4.60
N/A
P/E Ratio
N/A
N/A
Revenue Growth
23.29
N/A
52 Week Low
$10.95
$4.52
52 Week High
$23.02
$26.95

Technical Indicators

Market Signals
Indicator
SDGR
CRVS
Relative Strength Index (RSI) 78.03 56.54
Support Level $17.26 $14.24
Resistance Level $19.51 $16.66
Average True Range (ATR) 0.77 0.69
MACD 0.41 0.04
Stochastic Oscillator 98.06 96.61

Price Performance

Historical Comparison
SDGR
CRVS

About SDGR Schrodinger Inc.

Schrodinger Inc is a healthcare-based software company. It offers software solutions designed to support and accelerate the discovery, design, and optimization of molecules. The company operates in two reportable segments: Software and Drug Discovery. The software segment is focused on selling software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The drug discovery segment is focused on generating revenue from a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have various stages of discovery and development. The majority of the company's revenue is derived from the Software segment. Geographically, it derives the maximum revenue from the United States.

About CRVS Corvus Pharmaceuticals Inc.

Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.

Share on Social Networks: